Histotripsy for Renal Cell Carcinoma

The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.

Trial Details

NCT ID
NCT07943143
Phase
NA
Sponsor
The University of Hong Kong
Status
RECRUITING
Cancer Type
Clear Cell Renal Cell Carcinoma Kidney Cancer
Interventions
  • HistoSonics® Edison System (US)
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • Age ≥ 18 years old
  • Fit for general anaesthesia
  • Histologically confirmed renal cell carcinoma; radiological diagnosis acceptable if biopsy is not feasible
  • With or without distant metastases

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Renal Cell Carcinoma Kidney Cancer Trials on Trialify →